NCT01468324View on ClinicalTrials.gov

AZD7451 for Recurrent Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 5, 2011

Primary Completion Date

April 23, 2014

Study Completion Date

April 23, 2014

Conditions
Glioblastoma Multiforme
Interventions
DRUG

AZD7451

Depending on dose level, AZD7451 will be given once daily for 28 day cycles.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01468324 - AZD7451 for Recurrent Gliomas | Biotech Hunter | Biotech Hunter